InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,162.14
(
0.67%
)
US TECH 100
17,530.60
(
0.64%
)
Dow Jones
38,789.05
(
0.29%
)
Brent Oil
83.04
(
-0.11%
)
Bitcoin
63,014.73
(
-1.54%
)
Post# of 251725
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119575
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 207768

Tuesday, 02/21/2017 5:47:41 PM

Tuesday, February 21, 2017 5:47:41 PM

Post# of 251725
EXAS +13% on 4Q16 results /2017 guidance:

http://finance.yahoo.com/news/exact-sciences-generated-99-4-110000913.html

During the fourth quarter of 2016, the company generated revenues of $35.2 million and completed approximately 82,000 Cologuard tests. Fourth-quarter 2016 revenues and test volume grew 144 percent and 114 percent from the same period of 2015, respectively.

… The company anticipates revenue of $170-$180 million and Cologuard volume of at least 415,000 completed tests during 2017. During the first quarter of 2017, the company expects Cologuard volume of at least 88,000 completed tests.

The 2017 guidance for 415K tests is a 70% increase relative to the 244K tests completed in 2016; however, EXAS is still not profitable and has not given explicit guidance as to when it will be.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up